6/29/23, 11:41 PM SAVE (captopril) Pathway Feedback Search Clinical Topics Home Studies SAVE (captopril) SAVE (captopril) Disease Disease Non-ST-elevation myocardial inf ST-elevation myocardial infarction Trial question What is the role of captopril in patients with asymptomatic LV dysfunction after myocardial infarction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 17.0% female N = 2231 83.0% male 2231 patients (390 female, 1841 male) Inclusion criteria: patients with asymptomatic LV dysfunction after myocardial infarction Key exclusion criteria: contraindications to an ACE inhibitor, serum creatinine > 2.5 mg/dL, or comorbidities believed to limit survival Interventions N=1115 captopril (target dose 25 mg PO TID) N=1116 placebo (matching capsules) Primary outcome All-cause death https://web.pathway.md/studies/rechTdDJ8AN3dN9iO 1/2 6/29/23, 11:42 PM SAVE (captopril) Pathway 25.0 % 25 20 18.8 % 12.5 % Significant increase 6.3 % NNH = 20 0.0 % Captopril Placebo Significant increase in all-cause death (20% vs. 25%; RR 19, 95% CI 3 to 32) Secondary outcomes Significant increase in cardiovascular death (44.5% vs. 55.4%; RR 21, 95% CI 5 to 35) Significant increase in new-onset severe HF (11% vs. 16%; RR 37, 95% CI 20 to 50) Conclusion In patients with asymptomatic LV dysfunction after myocardial infarction, captopril was superior to placebo with respect to a all-cause death. Reference Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669-77. Open reference URL https://web.pathway.md/studies/rechTdDJ8AN3dN9iO 2/2